Close Menu

More articles about Business, Policy & Funding

The infectious disease testing firm has developed a sequencing-based coronavirus assay, which it plans to commercialize through its sister firm BioID Genomics. 

The investment bank gave shares of the Temple City, California-based genetic testing company a buy rating and a $20 price target.

The deal will join Tangen's GeneSpark point-of-care instrument with LabWare's portable disease surveillance kit for SARS-CoV-2.

The company said that a large portion of the offering's proceeds would be used to end criminal and civil investigations over its past billing practices.

The test uses a proprietary at-home PCR nasal swab test with a turnaround time of 24 hours and is authorized for use by at-risk people.

UrSure is developing and commercializing products that measure adherence to HIV medications, including pre-exposure prophylaxis, or PrEP.

The company said that by the end of June it would have made available more than 500,000 kits, which allow individuals to self-collect nasal samples at home.

The award will support assay development on the INSTI system, which has global regulatory approvals for HIV testing.

The recommendations are intended to improve testing capacity for SARS-CoV-2 by providing ways to combat testing supply shortages and expanding funding, among other steps.

The reference panel is an independent performance validation step for SARS-CoV-2 tests that are being used for clinical, not research, purposes.

The study will compare whole-genome sequencing and RNA sequencing to conventional diagnostic methods in about 450 acute leukemia patients in Sweden.

Webb Diagnostic has placed an initial order worth about C$3.5 million for MedMira's RevealCOVID-19 Total Antibody Test.

The assays quantitatively measure the activity of galactose-1-phosphate uridylyltransferase and biotinidase enzymes from newborn dried blood spot specimens.

The decline was attributed to SARS-CoV-2's impact on sales of Trinity's infectious disease and diabetes products, as well as its autoimmune testing services.

The bills would award grants to help public health laboratories purchase high-throughput instruments and to help support diagnostic testing outside of the lab setting.

The tests will run on Bosch's automated Vivalytic platform, with BioGX developing, manufacturing, and supplying reagents for the cartridges.

The test kit is designed to detect regions of the virus' nucleocapsid and envelope genes in upper respiratory specimens and bronchoalveolar lavage.

The Dutch firm announced a deal earlier in the month to develop the test with Duke-NUS Medical School and the Diagnostics Development Hub in Singapore.

Todos said it believes that gaining access to a medical grade ventilator will bring further attention to its coronavirus tests.

The approval was based on data showing superior efficacy for Alunbrig compared to Pfizer's Xalkori, especially in patients with brain metastasis.

Pages